Фокально-сегментарный гломерулосклероз: фокус на циклоспорин


Л.В. Козловская

ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, Москва
Представлены подходы к лечению фокально-сегментарного гломерулосклероза и их патогенетическое обоснование; специально обсуждаются показания к назначению циклоспорина.

Литература


1. Haas M., Spargo B.H., Coventry S. Increasing incidence of focalsegmentalglomerulosclerosis among adult nephropathies: a 20-year renalbiopsy study. Am. J. Kidney Dis. 1995; 26: 740–750.


2. Barisoni L., Valeri A., Radhakrishnan J. et al. Focal segmentalglomerulosclerosis: a 20-year epidemiological perspective. J. Am. Soc.Nephrol. 1994; 5: 347–354.


3. Korbet S.M., Genchi R., Borok R.Z., Schwartz M.M. The racial differenceof glomerular lesions in nephrotic adults. Am. J. Kidney Dis. 1996; 27:647–651.


4. Lee D.Y., Kim W., Kang S.K. et al. Angiotensin-converting enzyme genepolymorphism in patients with minimal change nephrotic syndrome andfocal segmental glomerulosclerosis. Nephron. 1997; 77(4): 471–473.


5. Gheissari A., Salehi M., Dastjerdi S.B. et al. Angiotensin-convertingenzyme gene polymorphism and the progression rate of focal segmentalglomerulosclerosis in Iranian children. Nephrology (Carlton). 2008;13(8): 708–711.


6. Dixit M., Mansur A., Dixit N. et al. The role of ACE gene polymorphism inrapidity of progression of focal segmental glomerulosclerosis. J. Postgrad.Med. 2002; 48(4): 266–269.


7. Bantis C., Heering P.J., Luther Y. et al. Influence of cytokine genepolymorphisms on focal segmental glomerulosclerosis. Am. J. Nephrol.2004; 24(4): 427–431.


8. Dai S., Wang Z., Pan X. et al. ACTN4 gene mutations and single nucleotidepolymorphisms in idiopathic focal segmental glomerulosclerosis. Nephron.Clin. Pract. 2009; 111(2): c87–c94.


9. Munkert A., Helmchen U., Kemper MJ. et al. Characterization of thetranscriptional regulation of the human MT1-MMP gene and associationof risk reduction for focal-segmental glomerulosclerosis with two functionalpromoter SNPs. Nephrol. Dial. Transplant. 2009; 24(3): 735–742.


10. Barakat A.J., Arianas P., Glick A.D. et al. Focal sclerosing glomerulonephritisin a child with Laurence-Moon-Biedl syndrome. Child. Urol. Nephrol.1990; 10: 109–111.


11. Hara M., Ichida F., Higuchi A. et al. Nephropathy associated withCharcot-Mari-Tooth disease. Int. J. Pediatr. Nephrol. 1984; 5: 99–102.


12. Scaglia F., Vogel H., Hawkins E.P. et al. Novel homoplasmic mutation inthe mitochondrial tRNATyr gene associated with atypical mitochondrialcytopathy presenting with focal segmental glomerulosclerosis. Am. J. Med.Genet. 2003; 123A(2): 172–178.


13. Hotta O., Inoue C.N., Miyabayashi S. et al. Clinical and pathologic featuresof focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR)gene mutation. Kidney Int. 2001; 59(4): 1236–1243.


14. Benetti E., Caridi G., Malaventura C. et al. A novel WT1 gene mutationin a three-generation family with progressive isolated focal segmentalglomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2010; 5(4): 698–702.


15. Orloff M.S., Iyengar S.K., Winkler C.A. et al. Variants in the Wilmsc tumorgene are associated with focal segmental glomerulosclerosis in the AfricanAmerican population. Physiol. Genomics. 2005; 21(2): 212–221.


16. Schlondorff J., Del Camino D., Carrasquillo R. et al. TRPC6 mutationsassociated with focal segmental glomerulosclerosis cause constitutiveactivation of NFAT-dependent transcription. Am. J. Physiol. Cell. Physiol.2009; 296(3): C558–C569.


17. Kopp J.B., Smith M.W., Nelson G.W. et al. MYH9 is a major-effect riskgene for focal segmental glomerulosclerosis. Nat. Genet. 2008; 40(10):1175–1184.


18. Freedman B.I., Hicks P.J., Bostrom M.A. et al. Polymorphisms in the nonmusclemyosin heavy chain 9 gene (MYH9) are strongly associated withend-stage renal disease historically attributed to hypertension in AfricanAmericans. Kidney Int. 2009; 75(7): 736–745.


19. Freedman B.I., Hicks P.J., Bostrom M.A. et al. Non-muscle myosin heavychain 9 gene MYH9 associations in African Americans with clinicallydiagnosed type 2 diabetes mellitus-associated ESRD. Nephrol. Dial.Transplant. 2009; 24(11): 3366–3371.


20. Lowik M.M., Groenen P.J., Levtchenko E.N. Molecular genetic analysisof podocyte genes in focal segmental glomerulosclerosis – a review. Eur. J.Pediatr. 2009; 168(11): 1291–1304.


21. Franceschini N., North K.E., Kopp J.B. et al. NPHS2 gene, nephriticsyndrome and focal segmental glomerulosclerosis: a HuGE review. Genet.Med. 2006; 8(2): 63–75.


22. Brown E.J., Schlondorff J.S., Becker D.J. et al. Mutations in the forminggene INF2 cause focal segmental glomerulosclerosis. Nat. Genet. 2010;42(1): 72–76.


23. Lavin P.J., Gbadegesin R., Damodaran T.V., Winn M.P. Therapeutictargets in focal and segmental glomerulosclerosis. Curr. Opin Nephrol.Hypertens. 2008; 17(4): 386–392.


24. Camici M. Urinary detection of podocyte injury. Biomed. Pharmacother.2007; 61: 245–249.


25. Dc Agati V.D. Podocyte injury in focal segmental glomerulosclerosis:Lessons from animal models (a play in five acts). Kidney Int. 2008; 73(4):399–406.


26. Yoshikawa N., Ito H., Akamatsu R. et al. Glomerular podocyte vacuolationin focal segmental glomerulosclerosis. Arch. Pathol. Lab. Med. 1986;110(5): 394–398.


27. Chiang M.L., Hawkins E.P., Berry P.L. et al. Diagnostic and prognosticsignificance of glomerular epithelial cell vacuolization and podocyteeffacementin children with minimal lesion nephrotic syndrome and focalsegmental glomerulosclerosis: an ultrastructural study. Clin. Nephrol.1988; 30(1): 8–14.


28. Kihara I., Tsuchida S., Yaoita E. et al. Podocyte detachment and epithelialcell reaction in focal segmental glomerulosclerosis with cellular variants.Kidney Int. Suppl. 1997; 63: S171–S176.


29. Schwartz M.M. The role of podocyte injury in the pathogenesis of focalsegmental glomerulosclerosis. Ren. Fail. 2000; 22(6): 663 –684.


30. Michaud J.L., Lemieux L.I., Dube M. et al. Focal and segmentalglomerulosclerosis in mice with podocyte-specific expression of mutantalpha actinin-4. J. Am. Soc. Nephrol. 2003; 14(5): 1200–1211.


31. Chen C.A., Hwang J.C., Guh J.Y. et al. Reduced podocyte expression ofalpha3beta1 integrins and podocyte depletion in patients with primary focalsegmental glomerulosclerosis and chronic PAN treated rats. J. Lab. Clin.Med. 2006; 147(2): 74–82.


32. Shi S.F., Wang S.X., Zhang Y.K. et al. Ultrastructural features andexpression of cytoskeleton proteins of podocyte from patients with minimalchange disease and focal segmental glomerulosclerosis. Ren. Fail. 2008;30(5): 477–483.


33. Deegens J.K., Dijkman H.B., Borm GF. et al. Podocyte foot processeffacement as a diagnostic tool in focal segmental glomerulosclerosis.Kidney Int. 2008; 74(12): 1568–1576.


34. Gassler N., Elger M., Kranzlin B. et al. Podocyte injury underlies theprogression of focal segmental glomerulosclerosis in the fa/fa Zucker rat.Kidney Int. 2001; 60(1): 106–116.


35. Korbet S.M. Primary focal segmental focal segmental glomerulosclerosis.Brady H.R., Wilcox C.S. (ed.) Therapy in nephrology and hypertension.Saunders., 2003: 223–236.


36. Meyrier A., Collaborative Group of the Societe de Nephrologie. Cyclosporinin the treatment of neprosis. Am. J. Nephrol. 1989; 9(Suppl. 1): 65–71.


37. Melocoton T.L., Kamil E.S., Cohen A.H., Fine R.N. Long-term cyclosporineA treatment of steroid-resistant and steroid-dependent nephritic syndrome.Am. J. Kidney Dis. 1991; 18: 583–588.


38. Cattran D.C. Cyclosporine in the treatment of idiopathic focal segmentalglomerulosclerosis. Semin. Nephrol. 2003; 23(2): 234–241.


39. Chishti A.S., Sorof J.M., Brewer E.D., Kale A.S. Long-term treatment offocal segmental glomerulosclerosis in children with cyclosporine given as asingle daily dose. Am. J. Kidney Dis. 2001; 38(4): 754–760.


40. Цыгин А.Н., Леонова А.В., Кучеренко А.Г. и др. Терапия циклоспориномА детей с фокально-сегментарным гломерулосклерозом. Вопросысовременнойпедиатрии 2009; 5: 93–97.


41. Lieberman K.V., Tejani A. A randomized double-blind placebo-controlledtrial of cyclosporine in steroid-resistant idiopathic focal segmentalglomerulosclerosis in children. J. Am. Soc. Nephrol. 1996; 7(1): 56–63.


42. Сameron J.S. Focal segmental glomerulosclerosis in adults. Nephrol. Dial.Transplant. 2003; 18 (Suppl. 6): vi45–vi51.


43. Lee H.Y., Kim H.S., Kang C.M. et al. The efficacy of cyclosporine A inadult nephrotic syndrome with minimal change disease and focal-segmentalglomerulosclerosis: a multicenter study in Korea. Clin. Nephrol. 1995;43(6): 375–381.


44. Cattran D.C., Appel G.B., Hebert L.A. et al. A randomized trial ofcyclosporine in patients with steroid-resistant focal segmentalglomerulosclerosis. North America Nephrotic Syndrome Study Group.Kidney Int. 1999; 56(6): 2220–2226.


45. Heering P., Braun N., Mullejans R. et al.; German CollaborativeGlomerulonephritis Study Group. Cyclosporine A and chlorambucil in thetreatment of idiopathic focal segmental glomerulosclerosis. Am. J. KidneyDis. 2004; 43(1): 10–18.


46. Goumenos D.S., Tsagalis G., El Nahas A.M. et al.Immunosuppressivetreatment of idiopathic focal segmental glomerulosclerosis: a five-yearfollow-up study. Nephron. Clin. Pract. 2006; 104(2): c75–c82.


47. Braun N., Schmutzler F., Lange C. et al. Immunosuppressive treatment forfocal segmental glomerulosclerosis in adults. Cochrane Database Syst. Rev.2008; (3):CD003233.


48. Echigoya M.H., Obikane K., Nakashima T. et al. Glomerular localizationof erythropoietin receptor mRNA and protein in neonatal and mature mousekidney. Nephron. Exp. Nephrol. 2005; 100: e21–e29.


49. Logar C.M., Brinkkoetter P.T., Krofft R.D. et al. Darbepoetin alfaprotects podocytes from apoptosis in vitro and in vivo. Kidney Int. 2007;72: 489–498.


50. Joy M.S., Gipson D.S., Dike M. et al. Phase I trial of rosiglitazone inFSGS: I. Report of the FONT Study Group. Clin. J. Am. Soc. Nephrol.2009; 4(1): 39–47.


51. Joy M.S., Gipson D.S., Powell L. et al. Phase 1 trial of adalimumab inFocal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT(Novel Therapies for Resistant FSGS) study group. Am. J. Kidney Dis.2010; 55(1): 50–60.


52. Peyser A., Machardy N., Tarapore F. et al. Follow-up of phase I trial ofadalimumab and rosiglitazone in FSGS: III. Report of the FONT studygroup. BMC Nephrol. 2010; 11: 2.


Об авторах / Для корреспонденции


Козловская Л.В. – профессор кафедры терапии и профболезней МПФ, ведущий научный сотрудник отдела нефрологии Научно-исследовательского центра ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, д.м.н.
E-mail: knvpb@mma.ru


Похожие статьи


Бионика Медиа